ETF Comparison: ARKG vs FHLC
ETFã®èª¬æ
ARKG - ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF is an actively managed fund that invests in companies driving advancements in genomics, gene editing, genetic therapy, molecular diagnostics, and stem cell advances. The fund's portfolio is tilted towards smaller firms and is designed to capture long-term growth potential in the healthcare and biotechnology sectors.
FHLC - Fidelity MSCI Health Care Index ETF
The Fidelity MSCI Health Care Index ETF (FHLC) is a US-based equity fund that tracks the MSCI US IMI 25/50 Health Care Index, providing broad exposure to the healthcare market. With a competitive expense ratio and a diversified portfolio of nearly 400 stocks, including large-cap and small-cap companies, FHLC offers a growth-oriented investment approach.
æ¯èŒããŒãã«
| ARKG | FHLC | |
|---|---|---|
| ãã¡ã³ãå | ARK Genomic Revolution ETF | Fidelity MSCI Health Care Index ETF |
| Fund Provider | ARK Invest | Fidelity |
| Index | Active (No Index) | MSCI US IMI 25/50 Health Care |
| Asset Class | Equity | Equity |
| Listing | US-listed | US-listed |
| Expense Ratio | 0.75% | 0.08% |
| Inception Date | 2014-10-31 | 2013-10-21 |
| Number Of Holdings | 42 | 364 |
| Region | United States | United States |
| Investment Style | Growth | Growth |
| Market Cap | Blend | Large-Cap |
| Sector | Healthcare | Healthcare |
| Sector Detail | Biotechnology | Health Care |
| Leveraged | Non-leveraged | Non-leveraged |
ããã¯ãã¹ããªãã·ã§ã³
ãµããªãŒ
äž»èŠææš
ããã©ãŒãã³ã¹ææš
ãªã¹ã¯ææš
詳现ãªã¿ãŒã³
ããã©ãŒãã³ã¹åæ
ããã©ãŒãã³ã¹åæã¯ã环ç©ãªã¿ãŒã³ã幎æ«ïŒEoYïŒãªã¿ãŒã³ãSharpeã¬ã·ãªãSortinoã¬ã·ãªãªã©ã®ãªã¹ã¯èª¿æŽæžã¿ææšãéããŠãæè³æŠç¥ã®ãªã¿ãŒã³ãè©äŸ¡ããããã«éå»ããŒã¿ãè©äŸ¡ããŸããããã«ãããæè³å®¶ã¯ããŸããŸãªåžå Žç°å¢ã§ã®çµ¶å¯Ÿçããã³çžå¯Ÿçãªããã©ãŒãã³ã¹ãè©äŸ¡ã§ããŸãã
环ç©ãªã¿ãŒã³
幎æ«ãªã¿ãŒã³ããŒãã«
幎æ«ãªã¿ãŒã³
ãªã¹ã¯åæ
ãªã¹ã¯åæãšã¯ãè³æ¬ã®æå€±ã«ã€ãªããå¯èœæ§ã®ããæœåšçãªãã¬ãã£ãã€ãã³ãã®è©äŸ¡ãæããŸãããªã¹ã¯åæã宿œããããšã§ãæè³ãè¡ãã¹ããã©ããã®å€æã«åœ¹ç«ãŠãããšãã§ããŸããããã¯ãæè³æŠç¥ã®äžè²«æ§ã«å¯Ÿããå©å®³é¢ä¿è ã®ä¿¡é Œãåæ ãããããŒããŠã³ããã©ãã£ãªãã£ãããŒã¿ãªã©ã®ãªã¹ã¯ææšã䜿çšããŠè¡ãããŸãã
ãããŒããŠã³
ãããŒããŠã³ããŒãã«
ã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³
ã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³ã¯ãéå»ã®è³ç£äŸ¡æ ŒããŒã¿ããã®ã©ã³ãã ãµã³ããªã³ã°ãéããŠå¹ åºãæœåšçãªçµæãçæããããšã§ãããŒããã©ãªãªã®ãªã¿ãŒã³ãäºæž¬ããããã«äœ¿çšãããçµ±èšçææ³ã§ããããŸããŸãªåžå Žæ¡ä»¶äžã§ã®ããŒããã©ãªãªã®æœåšçãªãªã¹ã¯ãšãªã¿ãŒã³ãè©äŸ¡ããã®ã«åœ¹ç«ã¡ãŸãããã®ã·ãã¥ã¬ãŒã·ã§ã³ã¯åææè³ãèæ ®ããå®é¡ç©ç«ãå®é¡åŒãåºããå²ååŒãåºããªã©ã®ãã£ãã·ã¥ãããŒã·ããªãªããªãã·ã§ã³ã§ã·ãã¥ã¬ãŒãããŸãã
éèŠïŒã¢ã³ãã«ã«ãã·ãã¥ã¬ãŒã·ã§ã³ã«ãã£ãŠçæãããäºæž¬ã¯çŽç²ã«ä»®èª¬çãªãã®ã§ãããå°æ¥ã®ãªã¿ãŒã³ãä¿èšŒãããã®ã§ã¯ãããŸãããæè³å€æã¯ããŸããŸãªèŠå ãèæ ®ããäžã§è¡ãã¹ãã§ãããéå»ã®ããã©ãŒãã³ã¹ã¯å°æ¥ã®çµæã瀺ããã®ã§ã¯ãããŸããã